Study #2015-0814
WISP (Women Choosing Surgical Prevention)
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy with delayed oophorectomy (ISDO) is surgery to remove the fallopian tubes. It is not known whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the sexual function and psychosocial well-being in patients with genetic mutation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Deleterious BARD1 Gene Mutation;Deleterious BRCA1 Gene Mutation;Deleterious BRCA2 Gene Mutation;Deleterious BRIP1 Gene Mutation;Deleterious EPCAM Gene Mutation;Deleterious MLH1 Gene Mutation;Deleterious MSH2 Gene Mutation;Deleterious MSH6 Gene Mutation;Deleterious PALB2 Gene Mutation;Deleterious PMS2 Gene Mutation;Deleterious RAD51C Gene Mutation;Deleterious RAD51D Gene Mutation;Hereditary Breast and Ovarian Cancer Syndrome;Premenopausal
Study phase:
Not applicable
Physician name:
Roni Wilke
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.